积雪草苷对高脂血症金黄地鼠脂质调节及肝脏保护作用研究
|
摘要
目的研究积雪草苷对高脂饮食诱导高脂血症模型金黄地鼠血清及肝脏内脂质代谢的影响,探讨其血脂调节功能和肝脏保护作用。方法 60只叙利亚金黄地鼠随机分成6组:正常组,模型组,积雪草苷低剂量(15 mg/kg)、中剂量(30 mg/kg)、高剂量(60 mg/kg)组及血脂康(250 mg/kg)组,每组10只,给予相应药物灌胃,正常组和模型组给予等量溶剂,正常组喂养正常饲料,其余各组喂养高脂饲料。均给予4周。测量各组金黄地鼠血清中的总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、谷草转氨酶(AST)、谷丙转氨酶(ALT)水平,以及肝脏组织TC、TG、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)水平,选取各组同部位肝脏组织进行冰冻切片,并通过HE染色观察肝脏结构变化。结果与正常组比较,模型组血清TC、TG、LDL-C、TC/HDL-C、ALT、AST水平以及肝脏TC、TG水平升高(P<0.05,P<0.01),肝脏SOD、GSH-PX水平降低(P<0.01)。与模型组比较,各给药组血清TC、TG、LDL-C、TC/HDL-C水平以及肝脏TC、TG水平降低(P<0.01),肝脏SOD、GSH-PX水平升高(P<0.01),血脂康组与积雪草苷低、中剂量组的血清AST水平降低(P<0.01)。肝组织冰冻切片HE染色显示各给药组肝脏脂肪性病变较模型组减轻。结论积雪草苷可减轻高脂血症模型金黄地鼠的脂肪性病变并缓解肝脏受损程度,其机制可能与增强肝脏抗氧化作用、降低血脂及肝脂有关。
Objective To observe the effect of asiaticoside on blood lipids and liver lipids metabolism in golden hamster model of hyperlipidemia induced by the high-fat diet, and to explore its lipid regulating function and liver protection. Methods Totally 60 Syrian golden hamsters were randomly divided into 6 groups,i.e., normal group, model group, asiaticoside low dose group(15 mg/kg), asiaticoside middle dose group(30 mg/kg), asiaticoside high dose group(60 mg/kg), Xuezhikang group(250 mg/kg), 10 in each group. The normal group and model group were administered with the equal volume of solvent, the other groups were administered with respetive drugs by gastrogavage. The normal group was fed with general diet, and the other group was fed with high-fat diet for 4 weeks. The levels of the total cholesterol(TC), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), glutamate-private transaminase(ALT), glutamic-oxalacetic transaminase(AST) in serum, as well as the levels of TC,TG, superoxide dismutase(SOD) and glutathione peroxidase(GSH-PX) in liver tissue were measured. The structural changes of frozen section of the same part of liver tissue in all groups were observed by Hematoxylin-Eosin staining. ResultsCompared with the normal group, the serum levels of TC,TG,LDL-C,TC/HDL-C, ALT,AST, and the hepatic levels of TC and TG were increased(P<0.05, P<0.01),the hepatic SOD and GSH-PX were decreased in the model group(P<0.01). Compared with the model group, the serum levels of TC,TG,LDL-C,TC/HDL-C, and the hepatic levels of TC and TG were decreased(P<0.01), the hepatic SOD and GSH-PX increased in the medication groups(P<0.01), the serum levels of AST was decreased in Xuezhikang group, asiaticoside low and middle dose groups(P<0.01).The HE staining results illustrated that fat deposition in the liver was reduced in the medication groups compared with the model group. Conclusion Asiaticoside can reduce fatty lesions and alleviate liver damage in golden hamster hyperlipidemic model, its mechanism may related to strengthening liver antioxidant effect, reducing blood lipids and liver lipids.
Objective To observe the effect of asiaticoside on blood lipids and liver lipids metabolism in golden hamster model of hyperlipidemia induced by the high-fat diet, and to explore its lipid regulating function and liver protection. Methods Totally 60 Syrian golden hamsters were randomly divided into 6 groups,i.e., normal group, model group, asiaticoside low dose group(15 mg/kg), asiaticoside middle dose group(30 mg/kg), asiaticoside high dose group(60 mg/kg), Xuezhikang group(250 mg/kg), 10 in each group. The normal group and model group were administered with the equal volume of solvent, the other groups were administered with respetive drugs by gastrogavage. The normal group was fed with general diet, and the other group was fed with high-fat diet for 4 weeks. The levels of the total cholesterol(TC), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), glutamate-private transaminase(ALT), glutamic-oxalacetic transaminase(AST) in serum, as well as the levels of TC,TG, superoxide dismutase(SOD) and glutathione peroxidase(GSH-PX) in liver tissue were measured. The structural changes of frozen section of the same part of liver tissue in all groups were observed by Hematoxylin-Eosin staining. ResultsCompared with the normal group, the serum levels of TC,TG,LDL-C,TC/HDL-C, ALT,AST, and the hepatic levels of TC and TG were increased(P<0.05, P<0.01),the hepatic SOD and GSH-PX were decreased in the model group(P<0.01). Compared with the model group, the serum levels of TC,TG,LDL-C,TC/HDL-C, and the hepatic levels of TC and TG were decreased(P<0.01), the hepatic SOD and GSH-PX increased in the medication groups(P<0.01), the serum levels of AST was decreased in Xuezhikang group, asiaticoside low and middle dose groups(P<0.01).The HE staining results illustrated that fat deposition in the liver was reduced in the medication groups compared with the model group. Conclusion Asiaticoside can reduce fatty lesions and alleviate liver damage in golden hamster hyperlipidemic model, its mechanism may related to strengthening liver antioxidant effect, reducing blood lipids and liver lipids.
引文
[1] Anum EA,Adera T.Hypercholesterolemia and coronary heart disease in the elderly:A meta-analysis[J].Ann Epidemiol,2004,14(9):705-721.
[2] 王文,刘明波,隋辉,等.中国心血管病的流行状况与防治对策[J].中国心血管病杂志,2012,17(5):321- 323.
[3] 中国心血管病中心.中国心血管病报告2017[M].北京:中国大百科全书出版社,2017:187.
[4] Stone NJ,Robinson JG,Lichtenstein AH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25 Pt B):2889-2934.
[5] Zhao D,Liu J,Xie W,et al.Cardiovascular risk assessment:a global perspective[J].Nat Rev Cardiol,2015,12(5):301-311.
[6] Jacobson TA,Ito MK,Maki KC,et al.National lipid association recommendations for patient-centered management of dyslipidemia:part 1—full report[J].J Clin Lipidol,2015,9(2):129-169.
[7] 舒萍.积雪草对高脂血症动物降血脂及肝脏的保护作用[D].厦门:厦门大学,2013.
[8] 胡慧明,朱彦陈,庞敏霞,等.实验性高脂血症动物模型比较分析[J].中国中药杂志,2016,41(20):3709-3714.
[9] Williams CL,Hayman LL,Daniels SR,et al.Cardiovascular health in childhood:A statement for health professionals from the Committee on Atherosclerosis,Hypertension,and Obesity in the Young(AHOY)of the Council on Cardiovascular Disease in the Young,American Heart Association[J].Circulation,2002,106(1):143-160.
[10] National Cholesterol Education Program.Report of the expertpanel on blood cholesterol levels in children and adolescent[J].Pediatrics,1992,89(2):525-584.
[11] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953.
[12] 郭宇杰,徐钧.积雪草苷药理作用的研究进展[J].山西医药杂志,2017,46(15):1829-1832.
[13] Srivastava RA,He S.Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster[J].Mol Cell Biochem,2010,345(1-2):197-206.
[14] 王艳辉,张洪友,杨威,等.胆固醇在哺乳动物体内的代谢调节[J].现代畜牧兽医,2016,45(11):53-57.
[15] 魏苏宁,苏雪莹,徐国恒.肝细胞甘油三酯代谢途径异常与脂肪肝[J].中国生物化学与分子生物学报,2016,32(2):123-132.
[16] 郑红琴,魏慧聪.血清ALT、AST和GGT水平检测在肝脏疾病诊断中的应用价值[J].河南医学研究,2018,27(24):4467-4468.
[17] 寇文镕.血脂康基础与临床研究现况概述[J].中国处方药,2005,4(7):62-67.
[18] 陈鸿鹏,谭晓风.超氧化物歧化酶(SOD)研究综述[J].经济林研究,2007,25(1):59-65.
[19] 白桂芹,成军,张树林.谷胱甘肽过氧化物酶与肝炎病毒蛋白关系的研究进展[J].胃肠病学和肝病学杂志,2004,13(1):82-84.
[2] 王文,刘明波,隋辉,等.中国心血管病的流行状况与防治对策[J].中国心血管病杂志,2012,17(5):321- 323.
[3] 中国心血管病中心.中国心血管病报告2017[M].北京:中国大百科全书出版社,2017:187.
[4] Stone NJ,Robinson JG,Lichtenstein AH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25 Pt B):2889-2934.
[5] Zhao D,Liu J,Xie W,et al.Cardiovascular risk assessment:a global perspective[J].Nat Rev Cardiol,2015,12(5):301-311.
[6] Jacobson TA,Ito MK,Maki KC,et al.National lipid association recommendations for patient-centered management of dyslipidemia:part 1—full report[J].J Clin Lipidol,2015,9(2):129-169.
[7] 舒萍.积雪草对高脂血症动物降血脂及肝脏的保护作用[D].厦门:厦门大学,2013.
[8] 胡慧明,朱彦陈,庞敏霞,等.实验性高脂血症动物模型比较分析[J].中国中药杂志,2016,41(20):3709-3714.
[9] Williams CL,Hayman LL,Daniels SR,et al.Cardiovascular health in childhood:A statement for health professionals from the Committee on Atherosclerosis,Hypertension,and Obesity in the Young(AHOY)of the Council on Cardiovascular Disease in the Young,American Heart Association[J].Circulation,2002,106(1):143-160.
[10] National Cholesterol Education Program.Report of the expertpanel on blood cholesterol levels in children and adolescent[J].Pediatrics,1992,89(2):525-584.
[11] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953.
[12] 郭宇杰,徐钧.积雪草苷药理作用的研究进展[J].山西医药杂志,2017,46(15):1829-1832.
[13] Srivastava RA,He S.Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster[J].Mol Cell Biochem,2010,345(1-2):197-206.
[14] 王艳辉,张洪友,杨威,等.胆固醇在哺乳动物体内的代谢调节[J].现代畜牧兽医,2016,45(11):53-57.
[15] 魏苏宁,苏雪莹,徐国恒.肝细胞甘油三酯代谢途径异常与脂肪肝[J].中国生物化学与分子生物学报,2016,32(2):123-132.
[16] 郑红琴,魏慧聪.血清ALT、AST和GGT水平检测在肝脏疾病诊断中的应用价值[J].河南医学研究,2018,27(24):4467-4468.
[17] 寇文镕.血脂康基础与临床研究现况概述[J].中国处方药,2005,4(7):62-67.
[18] 陈鸿鹏,谭晓风.超氧化物歧化酶(SOD)研究综述[J].经济林研究,2007,25(1):59-65.
[19] 白桂芹,成军,张树林.谷胱甘肽过氧化物酶与肝炎病毒蛋白关系的研究进展[J].胃肠病学和肝病学杂志,2004,13(1):82-84.